MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
22.60
+0.32
+1.44%
After Hours: 22.60 0 0.00% 17:29 12/01 EST
OPEN
22.35
PREV CLOSE
22.28
HIGH
22.76
LOW
22.07
VOLUME
1.20M
TURNOVER
0
52 WEEK HIGH
33.99
52 WEEK LOW
14.45
MARKET CAP
3.71B
P/E (TTM)
-24.7617
1D
5D
1M
3M
1Y
5Y
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
NASDAQ · 2d ago
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
NASDAQ · 2d ago
Acadia starts Phase 3 study for Prader-Willi hunger treatment
Acadia pharmaceuticals has initiated a phase 3 study for carbetocin nasal spray in the treatment of hyperphagia in patients with prader-willi syndrome. The rare genetic disorder causes near-constant feelings of hunger in patients. Currently there is no fda-approved treatment for the condition.
Seeking Alpha · 3d ago
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
NASDAQ · 4d ago
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
NASDAQ · 4d ago
ACADIA Pharmaceuticals: A Buy Rating on Promising Alzheimer’s Drug Prospects and Strategic Clinical Advancements
TipRanks · 5d ago
Acadia Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
NASDAQ · 5d ago
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. It also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.